CR Strategy & Innovation, Novartis AG
With close to 20 years of experience in CR and business ethics, Michael is currently having responsibilities for CR Strategy and Innovation at Novartis AG. He is primarily working on access to healthcare, inclusive business model innovation, measurement & evaluation and stakeholder engagement. Within his accountability to drive CR innovation, Michael was member of the PMO that was tasked with developing the inclusive business “Novartis Access” and is currently working with Novartis Social Business Unit on the implementation of the program (https://goo.gl/P7Zu5j). He has initiated and led the respective measurement & evaluation activities of Novartis Access that is conducted together with Boston University (https://goo.gl/HRoV4G). To support internal innovation efforts, Michael has developed and implemented an innovation fund that allows to seed fund new access to healthcare activities.
Michael is the Secretary of the CR Board of Novartis and an author and editor of articles and books in the areas of CR, social entrepreneurship, integrity management, risk and good governance. Michael has a PhD with honors (summa cum laude) and was awarded for his academic work (PhD thesis) with the Max Weber-Price for Business Ethics (2006).
INSEAD appointed him as a Social Entrepreneur in Residence and he is a recognized lecturer and speaker to students and executives at leading universities and business schools (e.g. INSEAD, IMD, Thunderbird, Cambridge University, HSG, Copenhagen Business School etc.).
He also extensively collaborated with faculty from Harvard Business School, Thunderbird et al. over a number of years to build skills of Novartis management population on topics such as integrity & compliance management and inclusive business model innovation.